Resyca, Recipharm’s joint venture with Medspray, has boarded its first pharmaceutical customer on the soft mist inhaler (SMI) platform. An agreement has been signed involving milestones and royalties for exclusivity on the specific drug product.   The SMI platform consists of a portable disposable nebulizer featuring a microspray nozzle developed by spray specialist Medspray, which is designed to generate a near-monodisperse aerosol with a high lung dose. The SMI device is purely mechanical, all...